TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 36447623
Drug: Standard neurological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard neurological rehabilitation + VR therapy
Study: 34916467
Drug: 1200 mg
Normalized name: aspirin 1200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200 mg rifampin
Study: 34916467
Drug: All doses
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All doses of rifampin
Study: 36412403
Drug: Gemcitabine (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gemcitabine (150 mg/m2 weekly)
Study: 36412403
Drug: Cisplatin (35
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (35 mg/m2 weekly)
Study: 32993388
Drug: Current pharmacological
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Current pharmacological treatments
Study: 32993388
Drug: Emerging pharmacological
Normalized name: salicylic acid
DrugBank: Salicylic acid (DB00936)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Emerging pharmacological treatments
Study: 35550261
Drug: BNT162b2 (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 (30 μg in 0.30 mL; full dose)
Study: 35550261
Drug: mRNA-1273 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: mRNA-1273 (50 μg in 0.25 mL; half dose)
Study: 32814500
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group watched the same video on a tablet once
Study: 616120592
Drug: EBI‐005 (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: EBI‐005 (5 or 20 mg/mL)
Study: 35298522
Drug: Hot pack
Normalized name: cold-hot pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hot pack treatment
Study: 34792290
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) sessions (n = 67)
Study: 33227224
Drug: Photobiomodulation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Photobiomodulation therapy (PBMT) applied over 14 sites per lower limb immediately before 1500 m run, delivering 30 J per site, total energy dose of 840 J.
Study: 34791771
Drug: Multi-plant extracts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-plant extracts product (oral intake for 12 weeks)
Study: 34791771
Drug: UV+high dose
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV+high dose group (0.500 g/kg.BW)
Study: 34791771
Drug: UV+moderate dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV+moderate dose group (0.250 g/kg.BW)
Study: 34791771
Drug: UV+low dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: UV+low dose group (0.125 g/kg.BW)
Study: 34791771
Drug: UV+high and
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: UV+high and moderate dose groups
Study: 33780928
Drug: 200 mL
Normalized name: Bag Top-Fill, 1200 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mL of water every 2 hours (1,600 mL per day)
Study: 33780928
Drug: 100 mL
Normalized name: PVC IV Bag 100 mL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mL of water every 2 hours (800 mL per day)
Study: 33780928
Drug: 110 mL
Normalized name: IODINE 110 mL in 10 L TOPICAL LIQUID [BoviSoft]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 110 mL of water every 1 hour (1,650 mL per day)
Study: 32819928
Drug: ENACT (Environmental
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENACT (Environmental enrichment for infants; parenting with Acceptance and Commitment Therapy)
Study: 34873117
Drug: Physical therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical therapy protocol based on physical exercise
Study: 34873117
Drug: Hospital's physical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hospital's physical therapy protocol
Study: 35582999
Drug: Mometasone nasal
Normalized name: mometasone nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone nasal spray for four weeks (M)
Study: 35582999
Drug: Mometasone nasal
Normalized name: mometasone nasal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mometasone nasal spray plus oral commercially available quail egg and zinc tablets (M+N)
Study: 35318738
Drug: 4 g
Normalized name: CTX4 Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 g rosemary leaf powder
Study: 35107239
Drug: Platelet-rich plasma
Normalized name: PLATELET-RICH PLASMA, AUTOLOGOUS
DrugBank: Platelet Rich Plasma (DB19295)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Platelet-rich plasma (PRP) treatment for ovarian rejuvenation
Study: 32306634
Drug: Noise-exposure +
Normalized name: Anthrax, post-exposure prophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Noise-exposure + doxycycline (50 mg/kg/d for 4 consecutive days)
Study: 33028101
Drug: PZ‐128 (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: PZ‐128 (0.3 or 0.5 mg/kg)
Study: 33028101
Drug: PZ‐128 (combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: PZ‐128 (combined doses)
Study: 33208752
Drug: SAFER pregnancy
Normalized name: Safe-Guard
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAFER pregnancy intervention (monthly group sessions, web-based platform, incentives for cessation)
Study: 35121638
Drug: Electronic monitoring
Normalized name: isopropyl alcohol
DrugBank: Isopropyl alcohol (DB02325)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Electronic monitoring feedback (EMF) with a Medication Event Monitoring System (MEMS) cap and motivational interviewing feedback.
Study: 33560097
Drug: Micafungin 100
Normalized name: micafungin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micafungin 100 mg daily
Study: 32529176
Drug: Needle-free insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Needle-free insulin injector (NFII)
Study: 32529176
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin pen (CIP)
Study: 32162352
Drug: Intravenous vitacoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vitacoxib (0.1 mg/kg)
Study: 32162352
Drug: Oral paste
Normalized name: Oral Paste
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral paste vitacoxib (0.1 mg/kg)
Study: 32162352
Drug: Oral tablet
Normalized name: Oral Tablet
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablet vitacoxib (0.1 mg/kg)
Study: 36695682
Drug: Low-dose cholecalciferol
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose cholecalciferol
Study: 35796481
Drug: Sodium oxybate
Normalized name: Sodium Oxybate
DrugBank: Sodium oxybate (DB09072)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium oxybate (3.3-3.9 g/day)
Study: 34142950
Drug: Generic clozapine
Normalized name: Clozapine
DrugBank: Clozapine (DB00363)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Generic clozapine (ChangZhou Pharmaceutical Factory Co. Ltd.) 100 mg twice daily for 10 days
Study: 34142950
Drug: Clozaril (HLS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozaril (HLS Therapeutics, Inc.) 100 mg twice daily for 10 days
Study: 37130044
Drug: Riluzole treatment
Normalized name: Riluzole
DrugBank: Riluzole (DB00740)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Riluzole treatment
Study: 34706374
Drug: TEA1 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEA1 (1000 mL with approximately 200,000 µg silicon/L)
Study: 34706374
Drug: TEA2 (1000
Approvals — FDA: no, EMA: no, PMDA: no
Description: TEA2 (1000 mL with approximately 750,000 µg silicon/L)
Study: 34706374
Drug: Si-low-Water (approximately
Approvals — FDA: no, EMA: no, PMDA: no
Description: Si-low-Water (approximately 10-10,000 µg silicon/L as a control)
Study: 33451926
Drug: Alfaxalone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone (15 mg kg−1) and midazolam (2 mg kg−1) with flumazenil (0.3 mg kg−1)
Study: 33451926
Drug: Alfaxalone (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfaxalone (15 mg kg−1) and midazolam (2 mg kg−1) with saline
Study: 32945236
Drug: Inappropriate time
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inappropriate time of spray
Study: 32945236
Drug: Frequency of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Frequency of spray
Study: 32945236
Drug: Long hours
Normalized name: long pepper extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long hours of daily chemical spray
Study: 32101915
Drug: Combination (group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination (group C)
Study: 35109685
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment group (ΔSBP15-60M)
Study: 35109685
Drug: Intensive treatment
Normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive treatment group (ΔSBP6-24H)
Study: 37638077
Drug: Inhaled methoxyflurane
Normalized name: methoxyflurane Nasal Inhalant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled methoxyflurane 3 ml
Study: 33676727
Drug: Fentanyl 25
Normalized name: FENTANYL 25MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 25 μg i.v.
Study: 33676727
Drug: Fentanyl 50
Normalized name: fentanyl 50 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 50 μg i.v.
Study: 34698342
Drug: Free distribution
Normalized name: acid red 337 free acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Free distribution of oral rehydration salts (ORS) via home deliveries prior to diarrhea onset
Study: 33550193
Drug: Rosemary essential
Normalized name: EUCALYPTOL 2.4 g in 100 g TOPICAL LIQUID [MELAO ROSEMARY ESSENTIAL Oil]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosemary essential oil inhalation (1 drop using a mask)
Study: 35468032
Drug: Group A:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group A: misoprostol 400 mcg vaginally and pyridoxine 40 mg sublingually
Study: 35468032
Drug: Group B:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Group B: misoprostol 400 mcg sublingually and pyridoxine 40 mg vaginally
Study: 33220066
Drug: High-dose flumazenil
Normalized name: Flumazenil
DrugBank: Flumazenil (DB01205)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose flumazenil (20 µg/kg)
Study: 33220066
Drug: Low-dose flumazenil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose flumazenil (10 µg/kg)
Study: 33529081
Drug: LEM5 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LEM5 treatment (5 g lemongrass/ewe/d)
Study: 33529081
Drug: LEM10 treatment
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: LEM10 treatment (10 g lemongrass/ewe/d)
Study: 33529081
Drug: Control (without
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (without supplement)
Study: 34848381
Drug: VP250 (250‐μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: VP250 (250‐μg peanut protein)
Study: 34511891
Drug: Tiotropium/Olodaterol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tiotropium/Olodaterol (5 μg/5 μg)
Study: 34189981
Drug: B12 fortified
Normalized name: Coenzyme B12
DrugBank: Cobamamide (DB11191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B12 fortified nutrient bar (2 μg)
Study: 34189981
Drug: B12 fortified
Normalized name: Coenzyme B12
DrugBank: Cobamamide (DB11191)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: B12 fortified yogurt (2 μg)
Study: 34189981
Drug: Propionibacterium (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propionibacterium (1 × 10^8 cfu/g)
Study: 33427870
Drug: Oral moxifloxacin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral moxifloxacin (400 mg/d for 7 days)
Study: 33427870
Drug: Intravenous ertapenem
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous ertapenem (1 g/d for 2 days) followed by oral levofloxacin (500 mg/d) and metronidazole (500 mg 3 times/d for 5 days)
Study: 34255745
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg in week 1, 1000 mg in week 2, 2000 mg daily for weeks 3-12)
Study: 33541306
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion (TCI) of propofol anesthesia
Study: 33541306
Drug: Manual infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual infusion (MI) of propofol anesthesia
Study: 33454272
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg daily for 6 months
Study: 35635652
Drug: Regorafenib dose-escalation
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib dose-escalation therapy starting at 80 mg/day, escalating to 120 mg/day in Week 2 and 160 mg/day in Week 3 if no severe toxicities observed.
Study: 35635652
Drug: Regorafenib standard
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib standard therapy (implied as a comparison).
Study: 32671481
Drug: Denosumab co-administered
Normalized name: Denosumab
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab co-administered with vitamin D (≥ 400 IU/day) and Ca (≥ 600 mg/day)
Study: 32671481
Drug: Placebo co-administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo co-administered with vitamin D (≥ 400 IU/day) and Ca (≥ 600 mg/day)
Study: 35507499
Drug: Conventional medical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medical therapy plus ICD
Study: 34658253
Drug: Insulin infusion
Normalized name: iLet Insulin Infusion 10-Pack Kit Inset
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin infusion to mimic prandial insulin response (full dose, 80% dose, 60% dose)
Study: 34658253
Drug: Glucagon infusion
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon infusion at 0.65 ng/kg/min (nonsuppressed day)
Study: 34658253
Drug: Glucagon infusion
Normalized name: Glucagon
DrugBank: Glucagon (DB00040)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Glucagon infusion at 0.65 ng/kg/min (suppressed day)
Study: 34658253
Drug: Multivariate regression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivariate regression analysis adjusted for age, sex, weight, and insulin dose
Study: 34954718
Drug: Monthly HIV
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly HIV self-testing and quarterly in-clinic testing
Study: 32533548
Drug: Acceptance and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acceptance and Commitment Therapy (ACT) for eight sessions
Study: 32533548
Drug: Conventional medications
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional medications and psycho-education (control group)
Study: 35383832
Drug: Rivaroxaban 2.5
Normalized name: rivaroxaban 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rivaroxaban 2.5 mg twice daily and Aspirin 100 mg once daily
Study: 36244667
Drug: Dexmedetomidine (DEX,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (DEX, 0.6 μg/kg)
Study: 33612197
Drug: Behavioral self-control
Normalized name: corticotropin
DrugBank: Corticotropin (DB01285)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Behavioral self-control therapy (BSCT)
Study: 34724084
Drug: Individual nutritional
Normalized name: Ocean Blue Nutritionals Omega-3 1450 Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Individual nutritional counseling every 2 weeks during therapy
Study: 34774334
Drug: Etelcalcetide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etelcalcetide (5 mg per dose intravenously)
Study: 33435287
Drug: Controlled-feeding Continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Controlled-feeding Continuous Energy Restriction (CER) - 25% daily energy restriction
Study: 35266148
Drug: Peanut oral
Normalized name: Peanut Oral Powder
Approvals — FDA: no, EMA: no, PMDA: no
Description: Peanut oral immunotherapy (POIT) with AR101
Study: 35266148
Drug: AR101 therapy
Normalized name: tetracycline
DrugBank: Tetracycline (DB00759)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AR101 therapy
Study: 32539121
Drug: Oral ibuprofen
Normalized name: ibuprofen Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ibuprofen (initial dose of 10 mg/kg followed by 5 mg/kg after 24 hours and a second 5 mg/kg dose after 48 hours)
Study: 34273071
Drug: All other
Normalized name: ALL OTHER THERAPEUTIC PRODUCTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: All other azole antifungals
Study: 36335411
Drug: Oral or
Normalized name: Doral Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral or sublingual mixed respiratory bacterial lysates (BLs)
Study: 36335411
Drug: Injected mixed
Normalized name: Humalog Mix Injectable Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injected mixed respiratory bacterial vaccines (BVs)
Study: 33730122
Drug: Nerve Growth
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve Growth Factor (NGF) injection into SCM
Study: 33730122
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline solution injection into SCM
Study: 35043507
Drug: Topically administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topically administered purified clinoptilolite-tuff (PCT)
Study: 32757963
Drug: PCT-guided discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: PCT-guided discontinuation of antimicrobials
Study: 32823510
Drug: Dietary practices
Normalized name: sodium phosphate, monobasic
DrugBank: Sodium phosphate, monobasic (DB09449)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dietary practices of adolescents (e.g., sugary snacks, breakfast consumption)
Study: 36261400
Drug: O-R toothbrush
Normalized name: OSTOMY SET,STERILE O.R.GUARDIAN H#4673
Approvals — FDA: no, EMA: no, PMDA: no
Description: O-R toothbrush (Oral-B iO with Radiant White brush head)
Study: 36261400
Drug: Manual toothbrush
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Manual toothbrush (Oral-B Indicator)
Study: 34254372
Drug: Cornus mas
Normalized name: Mielim Y Mas
DrugBank: Dextromethorphan (DB00514)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cornus mas L. fruit extract (CMFE)
Study: 35006328
Drug: Carbohydrate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate therapy (CHO) group received a 400‐mL carbohydrate drink 2‐3 hours before anesthesia
Study: 35006328
Drug: Carbohydrate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carbohydrate therapy (CHO) group
Study: 34760020
Drug: Garlic supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic supplementation (one tablet daily for three consecutive cycles)
Study: 34760020
Drug: Placebo (one
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (one tablet daily for three consecutive cycles)
Study: 36184780
Drug: tirzepatide 5
Normalized name: tirzepatide 5 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: tirzepatide 5 mg
Study: 36184780
Drug: tirzepatide 10
Normalized name: tirzepatide 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: tirzepatide 10 mg
Study: 36184780
Drug: tirzepatide 15
Normalized name: tirzepatide 15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: tirzepatide 15 mg
Study: 35998958
Drug: Perioperative support
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative support programme consisting of four face-to-face intervention sessions during the hospital stay and two weekly telephone follow-up sessions after discharge.
Study: 34096755
Drug: Psychedelic-assisted psychotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Psychedelic-assisted psychotherapy (PAP) using compounds such as MDMA, psilocybin, and LSD
Study: 32017253
Drug: Curcumin 1,000
Approvals — FDA: no, EMA: no, PMDA: no
Description: Curcumin 1,000 mg/day for 3 months
Study: 32617578
Drug: Aliskiren added
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aliskiren added to an angiotensin II receptor blocker (ARB)
Study: 36256673
Drug: Saline inhalation
Normalized name: Broncho Saline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline inhalation with SCT
Study: 36256673
Drug: Saline inhalation
Normalized name: Broncho Saline Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline inhalation with FET
Study: 33827349
Drug: High-Intensity Interval
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-Intensity Interval Cycling Exercise on Land (HIIE-L)
Study: 34101918
Drug: Sublingual dexmedetomidine
Normalized name: dexmedetomidine Sublingual Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sublingual dexmedetomidine
Study: 33109218
Drug: Lucerastat 1000
Normalized name: Lucerastat
DrugBank: Lucerastat (DB14872)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lucerastat 1000 mg
Study: 33109218
Drug: Lucerastat 4000
Normalized name: Lucerastat
DrugBank: Lucerastat (DB14872)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lucerastat 4000 mg
Study: 33109218
Drug: Lucerastat (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lucerastat (up to 4000 mg)
Study: 35978342
Drug: High-dose rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rifampicin (30 mg/kg/day) with isoniazid and pyrazinamide for 12 weeks after culture conversion.
Study: 35978342
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group treated with isoniazid, rifampicin (10 mg/kg/day), ethambutol, and pyrazinamide for 6 months.
Study: 35978342
Drug: High-dose rifampicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose rifampicin regimen.
Study: 34762532
Drug: Low-level green
Normalized name: Indocyanine Green
DrugBank: Indocyanine green (DB16024)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-level green laser (532 nm, 15 J/cm2 per treatment site)
Study: 35962633
Drug: Control treatment
Normalized name: SALICYLIC ACID 190 mg in 1 mL TOPICAL LIQUID [Derma E Acne Blemish Control Treatment Serum]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control treatment (CON)
Study: 36239176
Drug: Simultaneous implant
Normalized name: Fc fusion protein of a human inducible T cell costimulator ligand variant immunoglobulin domain designed to inhibit simultaneously the CD28 and ICOS inflammation pathways
DrugBank: Acazicolcept (DB18410)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous implant placement
Study: 36239176
Drug: Delayed implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implant placement (control)
Study: 35477518
Drug: Iberdomide 0.45
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iberdomide 0.45 mg